PCL, Inc. (KOSDAQ:241820)
South Korea flag South Korea · Delayed Price · Currency is KRW
302.00
-5.00 (-1.63%)
Mar 21, 2025, 5:32 PM KST

PCL, Inc. Company Description

PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services.

The company offers HiSU solution, an automated multi-immune diagnostic system that performs various diagnostics, high-speed tests including blood screening, multiple cancer screening, autoimmune testing, etc. It also provides antigen and antibody diagnostic kits, including PCLOK II anti-HIV/HCV/syphilis, and PCLOK II HBsAg/HIV p24.

In addition, the company offers platform services, such as SG ID for identifying novel target substances.

Further, it offers covid-19 solutions, such as PCLMD nCoV one step RT-PCR, PCL COVID19 speed RTPCR, PCLMD ABC multi RTPCR molecular diagnostic kits; PCL COVID19 Ag rapid FIA, and PCL COVID19 Ag gold antigen diagnostic kits; and PCL COVID19 IgG/IgM rapid gold, and PCL COVID19 total Ab EIA antibody diagnostic kits.

PCL, Inc. was incorporated in 2008 and is headquartered in Seoul, South Korea.

PCL, Inc.
CountrySouth Korea
Founded2008
IndustryMedical Devices
SectorHealthcare
Employees31
CEOSoyeon Kim

Contact Details

Address:
Star Valley, 99
Seoul, 08510
South Korea
Phone82 2 2144 3901
Websitepclchip.com

Stock Details

Ticker Symbol241820
ExchangeKOSDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyKRW
ISIN NumberKR7241820000
SIC Code2835

Key Executives

NamePosition
Soyeon KimChief Executive Officer